Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

FDA expands Igalmi approval to at-home use after phase 3 safety trial

Igalmi’s at-home approval adds safety evidence from an outpatient study to its earlier supervised-use authorization.

Published 17 Nov 2026· 5 minute read

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

CASRAI is the reference for research administration — bookmark it for the next question.

Teva announced on November 16, 2026 that the U.S. Food and Drug Administration had expanded Igalmi’s approval to at-home use for acute agitation in adults with schizophrenia, schizoaffective disorder, or bipolar I or II disorder. For clinical researchers, the development highlights how evidence about a treatment’s setting can extend an existing approval.

Updated labeling adds an unsupervised setting

The prescribing information revised in November 2026 now distinguishes healthcare-supervised and unsupervised settings for the dexmedetomidine film. It also specifies that Igalmi is not indicated to prevent agitation or treat the underlying psychiatric disorder, and that chronic daily use has not been studied.

In its November 16 announcement, Teva said the application for at-home use had been submitted on January 14, 2026 as a supplemental new drug application to the existing Igalmi application.

An extension of an existing approval

The FDA’s original approval letter for Igalmi is dated April 5, 2022. That decision covered acute agitation associated with schizophrenia or bipolar I or II disorder in adults. The April 2022 labeling required healthcare-provider supervision.

The earlier label described efficacy evidence from two randomized, double-blind, placebo-controlled studies conducted in clinical research units or hospitals. Their principal outcome assessed change in agitation using the Positive and Negative Syndrome Scale–Excited Component. This history places the new development in context: the product already had an approval, while the November expansion addresses its use beyond supervised healthcare facilities.

What the at-home trial evaluated

The SERENITY III registry record, NCT05658510, identifies BioXcel Therapeutics as sponsor and describes a randomized, blinded, placebo-controlled phase 3 study with two parts. Part 1 examined treatment in a clinic; Part 2 examined safety in the home setting over 12 weeks. The registry lists the study as completed, with an actual completion date of August 15, 2025. This distinction within the phase 3 research programme matters when interpreting the evidence behind the expansion.

For Part 2, the registered primary outcome was the incidence of serious adverse events and treatment-emergent adverse events compared with placebo. Secondary outcomes included interactions with emergency services related to agitation and adverse events leading to discontinuation. The protocol also described participant and informant involvement in completing an agitation episode diary. The registry names Worldwide Clinical Trials as a collaborator and identifies BioXcel as the responsible party for the record. Its eligibility section describes a separate consenting informant role alongside the enrolled participant.

The updated label’s outpatient safety study included 208 adults: 102 received Igalmi and 106 received placebo. Its most common adverse reactions included somnolence, dry mouth, dizziness, and altered sensation in the mouth. The label retains warnings concerning hypotension, orthostatic hypotension, bradycardia and QT interval prolongation.

In research terms, a serious adverse event outcome answers a different question from a symptom score. The home-setting safety endpoint should therefore remain distinct when teams summarize the earlier efficacy evidence and the additional evidence supporting this expansion.

Company reaction and independent coverage

Teva’s Chris Fox, executive vice president for U.S. Commercial and head of its Innovative Franchise, framed the approval around bringing treatment into a setting where patients experience episodes. Eric Hughes, Teva’s executive vice president for Global R&D and chief medical officer, emphasized changing where treatment can be delivered as part of neuroscience innovation.

AJMC’s November 16 report, by Giuliana Grossi and fact checked by Ashley Gallagher, emphasized the home study’s safety and tolerability endpoint. A separate Neuroscience Education Institute report likewise distinguished the earlier supervised efficacy studies from the additional home-setting safety evidence.

What the change means for academic research

As editorial analysis, the case offers university investigators a specific example of why the setting belongs alongside the population, comparator and endpoint in an evidence summary. A randomized controlled trial can address different questions within the same development programme. Describing both parts simply as an efficacy trial would obscure the purpose of the home-setting study.

For research offices assessing a proposed project, a useful comparison is between the setting in the approved labeling and the setting in the protocol being reviewed. Teams can then identify which evidence supports the proposed population and outcomes, and which questions their own project is intended to answer. These are implications for interpreting the evidence, rather than new institutional obligations created by this announcement.

The diary and informant elements also give trial-methods researchers concrete features to examine when considering data collection outside a facility. An analysis of such a design can distinguish what participants record, what informants contribute and how those observations relate to prespecified outcomes. Separately identifying safety outcomes and emergency-service use helps keep a description of the study aligned with its registered questions.

What happens next

Teva said it would announce commercialization plans for at-home use later. For academic teams following this development, that future company announcement is separate from the regulatory expansion already described in the updated label. The immediate research significance lies in the documented change of setting and the distinction between the earlier supervised efficacy studies and the home-setting safety study.

Sources

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →